Interpret the laboratory results of a 69‑year‑old male, which show mildly elevated aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, and a dyslipidemic profile with high total cholesterol and low‑density lipoprotein (LDL) cholesterol.

Laboratory Interpretation for 69-Year-Old Male

This patient has a hepatocellular pattern of mild liver enzyme elevation (AST 84, ALT 54, bilirubin 1.7) most consistent with nonalcoholic fatty liver disease (NAFLD), combined with significant dyslipidemia requiring statin therapy and lifestyle modification.

Liver Function Test Analysis

Pattern Recognition

The laboratory results show a hepatocellular predominant pattern with:

• AST elevated to 2.1× upper limit of normal (ULN)
• ALT elevated to 1.2× ULN
• Total bilirubin mildly elevated at 1.4× ULN
• Normal alkaline phosphatase (62 IU/L)

This represents mild aminotransferase elevation (<5× ULN) 1. The AST:ALT ratio of 1.6 suggests possible alcohol-related liver disease, though NAFLD remains most common in this demographic 1.

Most Likely Diagnosis

NAFLD is the leading cause, given:

• Prevalence of 20-30% in general population 1
• Mild aminotransferase elevation pattern
• Age and metabolic risk factors
• Normal synthetic function (albumin 4.8, normal BUN/Cr ratio)

The mildly elevated bilirubin (1.7 mg/dL) without cholestatic pattern is atypical for simple NAFLD and warrants consideration of Gilbert's syndrome as a concurrent benign condition 2.

Recommended Workup

Initial serologic testing should include:

• Hepatitis B surface antigen and hepatitis C antibody 3, 4
• Iron studies (ferritin, transferrin saturation) - to exclude hemochromatosis 1, 4
• Fasting glucose or HbA1c - already borderline at 97 mg/dL 4
• Thyroid function tests - AST can be elevated in thyroid disorders 1
• Alcohol use history - critical given AST:ALT ratio 1
• Medication/supplement review - including over-the-counter products 3, 4

If initial testing unremarkable:

• Abdominal ultrasound is the appropriate first-line imaging for suspected NAFLD 1
• Sensitivity 84.8% and specificity 93.6% for moderate-to-severe steatosis 1

Consider checking creatine kinase (CK) to exclude muscle source of AST elevation, particularly if patient exercises intensively or takes statins 2.

Clinical Pitfalls

The AST elevation (84 IU/L) can originate from non-hepatic sources including heart, skeletal muscle, kidneys, and red blood cells 1. The ALT is more liver-specific 1. If AST remains disproportionately elevated, consider:

• Hemolysis
• Myopathy
• Strenuous exercise
• Macro-AST (benign condition with AST-immunoglobulin complexes) 5

Lipid Profile Analysis

Cardiovascular Risk Assessment

The patient requires statin therapy based on:

• Total cholesterol 241 mg/dL (goal <200)
• LDL cholesterol 171 mg/dL (goal <100, ideally <70 for his age)
• LDL:HDL ratio 3.4 (acceptable but suboptimal)
• HDL 51 mg/dL (adequate at >39)
• Triglycerides 107 mg/dL (normal)

At age 69, this patient falls into a high-risk category for atherosclerotic cardiovascular disease (ASCVD) requiring aggressive lipid management 6, 7.

Statin Therapy Considerations

Statins are NOT contraindicated despite mildly elevated transaminases 7. Key points:

• Asymptomatic transaminase elevation >3× ULN is infrequent with statins and often resolves with dose adjustment 7
• Statins are safe in chronic stable liver disease including NAFLD, with potential benefit 7
• Baseline transaminases already obtained; routine monitoring is NOT recommended unless symptoms develop 7
• Measure transaminases only if signs/symptoms of hepatotoxicity emerge 7

Statin-associated hepatotoxicity is rare, and the cardiovascular benefit far outweighs theoretical liver risk in this patient 7.

Management Algorithm

Immediate actions:

1. Initiate moderate-to-high intensity statin therapy (e.g., atorvastatin 40-80 mg or rosuvastatin 20-40 mg) 6, 7
2. Lifestyle modification: Mediterranean diet, weight loss if overweight, regular exercise 6
3. Complete hepatitis and metabolic workup as outlined above 3, 4

Follow-up at 2-3 months:

• Repeat lipid panel to assess statin response
• Repeat liver enzymes (ALT, AST, bilirubin)
• If liver enzymes stable or improved: continue statin
• If liver enzymes worsen significantly (>3× baseline): evaluate for alternative causes before attributing to statin 7

If liver enzymes remain elevated after 6 months:

• Proceed with abdominal ultrasound 1
• Consider additional testing for uncommon causes (autoimmune hepatitis, alpha-1 antitrypsin, ceruloplasmin) 4
• Liver biopsy reserved for unclear diagnosis or concern for advanced fibrosis 1

Renal and Metabolic Parameters

The eGFR of 77 mL/min/1.73m² represents mild reduction (Stage 2 CKD if persistent), appropriate for age but warrants monitoring. The borderline glucose (97 mg/dL) indicates prediabetes risk, reinforcing the importance of lifestyle modification and potentially explaining the NAFLD pattern 1, 4, 8.